CellSource Co., Ltd. (4880.T)
JPY 844.0
(-1.97%)
JPY 844.0
(-1.97%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 77.29 Million JPY | 0.0% |
| 2022 | - JPY | 0.0% |
| 2021 | - JPY | -100.0% |
| 2020 | 1.09 Million JPY | -74.4% |
| 2019 | 4.28 Million JPY | 0.0% |
| 2018 | - JPY | 0.0% |
| 2017 | - JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | - JPY | 0.0% |
| 2024 Q2 | - JPY | 0.0% |
| 2024 Q1 | - JPY | 0.0% |
| 2023 Q4 | 77.29 Million JPY | 0.0% |
| 2023 FY | 77.29 Million JPY | 0.0% |
| 2023 Q3 | - JPY | 0.0% |
| 2023 Q2 | - JPY | 0.0% |
| 2023 Q1 | - JPY | 0.0% |
| 2022 Q2 | - JPY | 0.0% |
| 2022 Q1 | - JPY | 0.0% |
| 2022 Q4 | - JPY | 0.0% |
| 2022 FY | - JPY | 0.0% |
| 2022 Q3 | - JPY | 0.0% |
| 2021 Q1 | - JPY | -100.0% |
| 2021 Q2 | - JPY | 0.0% |
| 2021 Q3 | - JPY | 0.0% |
| 2021 Q4 | - JPY | 0.0% |
| 2021 FY | - JPY | -100.0% |
| 2020 FY | 1.09 Million JPY | -74.4% |
| 2020 Q1 | - JPY | -100.0% |
| 2020 Q4 | 1.09 Million JPY | 0.0% |
| 2020 Q3 | - JPY | 0.0% |
| 2020 Q2 | - JPY | 0.0% |
| 2019 Q3 | - JPY | 0.0% |
| 2019 Q4 | 4.28 Million JPY | 0.0% |
| 2019 FY | 4.28 Million JPY | 0.0% |
| 2018 FY | - JPY | 0.0% |
| 2017 FY | - JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 767.03 Million JPY | 89.923% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 2 Billion JPY | 96.135% |
| Linical Co., Ltd. | 1.49 Billion JPY | 94.847% |
| Trans Genic Inc. | 1.32 Billion JPY | 94.176% |
| MEDINET Co., Ltd. | 781 Thousand JPY | -9796.415% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.34 Billion JPY | 96.707% |
| AnGes, Inc. | 214.94 Million JPY | 64.042% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | 27.663% |
| Nxera Pharma Co., Ltd. | 63.21 Billion JPY | 99.878% |
| Immuno-Biological Laboratories Co., Ltd. | 84.56 Million JPY | 8.597% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 93.03% |
| Carna Biosciences, Inc. | 28.4 Million JPY | -172.132% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 875.59 Million JPY | 91.173% |
| RaQualia Pharma Inc. | 39.05 Million JPY | -97.928% |
| Chiome Bioscience Inc. | - JPY | -Infinity% |
| Kidswell Bio Corporation | 1.83 Billion JPY | 95.795% |
| PeptiDream Inc. | 19.63 Billion JPY | 99.606% |
| Oncolys BioPharma Inc. | 161.1 Million JPY | 52.023% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 397 Million JPY | 80.531% |
| Healios K.K. | 450 Million JPY | 82.824% |
| BrightPath Biotherapeutics Co., Ltd. | - JPY | -Infinity% |
| Kubota Pharmaceutical Holdings Co., Ltd. | - JPY | -Infinity% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 773.29 Million JPY | 90.005% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 788 Million JPY | 90.191% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 491.35 Million JPY | 84.27% |
| StemCell Institute Inc. | 6.67 Million JPY | -1057.744% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 143.75 Million JPY | 46.232% |